How Dr. Yasir Qazi embraced cell-free DNA surveillance, an unaffected approach due to the recent CMS update

Hear from our ProActive Study Investigator In this episode of our Inside the ProActive Study Podcast, Dr. Yasir Qazi talks to us about: • His dd-cfDNA “surveillance journey” and protocol development.

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on: • Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protoc

How Dr. Millie Samaniego bridged the gap between study use and routine care by extending protocolized use

In this episode of our Inside the ProActive Study Podcast, Dr. Millie Samaniego-Picota tells us about: • Her experience expanding the ProActive Study Protocol schedule to all her patients • How her

Inside the ProActive Study- How Dr Sanjeev Akkina and Dr. Jessica Coleman approach the continuity of transplant recipient care

How Dr. Anand championed a surveillance protocol informed by his deep experience and research

How Dr. Batarse advocates for his patients upon early recognition of subtle rejection using cfDNA

Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ

Meet Amanda, Colorectal Cancer Survivor and Signatera Patient

Amanda shares her powerful and unexpected journey. A routine genetic screening during her pregnancy led to a Stage IV colon cancer diagnosis. She underwent chemo while pregnant, had surgery after her

Redefining heart transplant care: How donor-derived cell-free DNA is transforming rejection surveillance

This webinar highlights the DEFINE-HT study initial results and the two-threshold algorithm: fraction + DQS.

Integrating ctDNA and utDNA Across the Bladder Cancer Continuum

From Detection to Direction: Signatera MRD testing and its impact in CRC